Physicians and scientists from Fred Hutchinson Cancer Center and UW Medicine are testing new treatments for ALL and finding new ways to use current treatments.
Through this work, we are looking for answers to two main questions: How can we do even better at controlling or curing ALL? How can we make treatments less toxic and easier on patients?
We have clinical trials for all classifications of ALL, from newly diagnosed to refractory. The trials are testing dozens of medicines, including:
- Chemotherapy regimens
- Targeted therapies
- Immunotherapies, including cellular immunotherapies
In the past 15 years, research on targeted therapies and immunotherapies has found new ways to put ALL into remission and make treatments less toxic for patients. Fred Hutch is a national leader in advancing these and other options, bringing new hope to patients.
When your care team designs your treatment plan, they will give you the choice to join clinical trials that match your situation. If you decide to join one, you will see the same physicians and nurses as you would for standard therapy.
Your care team will talk with you if you might want to join a particular study and why, so you can make the decision that’s best for you.
A Leading Certification for Treating ALL
Fred Hutch, and specifically the Bezos Family Immunotherapy Clinic, is one of only 51 centers certified for CAR-T therapy, an innovative immunotherapy treatment for ALL. Learn more about the treatment and this special designation.
Fred Hutch’s Dr. Turtle on the future of immunotherapy
In this Q&A with Fred Hutch’s Dr. Cameron Turtle, you can learn about his research into the development of therapies that redirect immune T cells to attack cancer cells.
A Second Chance to Make CAR-T Cell Therapy Work
For patients with aggressive bone cancers, could a second round of CAR-T therapy make a difference
Bone marrow transplant survival rates are on the rise
Fred Hutch has been tracking bone marrow transplant risks since the 1990s. They are reporting sharp declines in transplant-related complications, with the risk of post-transplant death down 34 percent.